[go: up one dir, main page]

MX2018011419A - Moduladores de receptores estrogénicos. - Google Patents

Moduladores de receptores estrogénicos.

Info

Publication number
MX2018011419A
MX2018011419A MX2018011419A MX2018011419A MX2018011419A MX 2018011419 A MX2018011419 A MX 2018011419A MX 2018011419 A MX2018011419 A MX 2018011419A MX 2018011419 A MX2018011419 A MX 2018011419A MX 2018011419 A MX2018011419 A MX 2018011419A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
receptor alpha
receptor modulators
compounds
formula
Prior art date
Application number
MX2018011419A
Other languages
English (en)
Other versions
MX392461B (es
Inventor
Qinhua Huang Peter
Helen Slee Deborah
Gajanan Hedge Sayee
Daniel Hopkins Chad
Duane Bunker Kevin
Robert Pinchman Joseph
Kumar Sit Rakesh
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of MX2018011419A publication Critical patent/MX2018011419A/es
Publication of MX392461B publication Critical patent/MX392461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la Fórmula (I) son moduladores de receptores estrogénicos alfa, donde las variables de la Fórmula (I) se describen en la descripción. Tales compuestos, así como sales farmacéuticamente ceptables y composiciones de estos, son útiles para tratar enfermedades o afecciones que son ependientes de receptores estrogénicos alfa y/o están mediadas por receptores estrogénicos alfa, que incluyen afecciones caracterizadas por proliferación celular excesiva, tales como cáncer de mama.
MX2018011419A 2016-04-01 2017-03-29 Moduladores de receptores estrogénicos MX392461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317254P 2016-04-01 2016-04-01
PCT/US2017/024809 WO2017172957A1 (en) 2016-04-01 2017-03-29 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
MX2018011419A true MX2018011419A (es) 2019-06-06
MX392461B MX392461B (es) 2025-03-11

Family

ID=59966438

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011419A MX392461B (es) 2016-04-01 2017-03-29 Moduladores de receptores estrogénicos
MX2022005780A MX2022005780A (es) 2016-04-01 2018-09-24 Moduladores de receptores estrogenicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005780A MX2022005780A (es) 2016-04-01 2018-09-24 Moduladores de receptores estrogenicos.

Country Status (15)

Country Link
US (5) US20190142811A1 (es)
EP (1) EP3442971B1 (es)
JP (2) JP6926189B2 (es)
KR (2) KR20220071293A (es)
CN (4) CN112679495B (es)
AR (1) AR108011A1 (es)
AU (3) AU2017242027B2 (es)
CA (1) CA3017388C (es)
ES (1) ES2991862T3 (es)
IL (3) IL285318B (es)
MX (2) MX392461B (es)
RU (1) RU2738646C2 (es)
SG (1) SG11201807708SA (es)
TW (2) TW202235418A (es)
WO (1) WO2017172957A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113004273A (zh) 2016-02-05 2021-06-22 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
SG11202001733VA (en) 2017-09-11 2020-03-30 Recurium Ip Holdings Llc Continuous flow processes for making bicyclic compounds
CN111315378A (zh) * 2017-11-16 2020-06-19 诺华股份有限公司 包含lsz102和瑞博西尼的药物组合
EP3978493A4 (en) * 2019-05-24 2023-02-01 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of acrylic acid derivatives, preparation method therefor and use thereof
EP3993787A4 (en) * 2019-08-06 2023-07-12 Recurium IP Holdings, LLC Estrogen receptor modulators for treating mutants
BR112022008520A2 (pt) * 2019-11-04 2022-07-26 Recurium Ip Holdings Llc Sais e formas de um modulador de receptor de estrogênio
WO2021127042A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
KR20220119419A (ko) * 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 복합제
CN115023224A (zh) * 2019-12-20 2022-09-06 里科瑞尔姆Ip控股有限责任公司 组合
AU2020408698A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
IL294067A (en) * 2019-12-20 2022-08-01 Recurium Ip Holdings Llc Combinations
CN117242055A (zh) * 2020-04-22 2023-12-15 里科瑞尔姆Ip控股有限责任公司 选择性雌激素受体降解剂的制备
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
EP4214192A4 (en) * 2020-09-20 2024-09-25 Tactogen Inc. BENEFICIAL TRYPTAMINE COMPOSITIONS FOR IMPROVING MENTAL DISORDERS
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
JP2024502270A (ja) * 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
AU2022305957A1 (en) * 2021-07-08 2024-01-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112958A0 (en) 1994-03-11 1995-06-29 Lilly Co Eli Method for treating 5ht2b receptor related conditions
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2006015035A1 (en) 2004-08-02 2006-02-09 Smithkline Beecham Corporation Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
CA3184380A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US8614340B2 (en) * 2009-07-28 2013-12-24 Ono Pharmaceuticals Co., Ltd. Bicyclic compound and use thereof for medical purposes
WO2011088025A1 (en) 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
CA2789622C (en) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US20130172320A1 (en) 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2012102357A1 (ja) * 2011-01-27 2012-08-02 小野薬品工業株式会社 二環式化合物およびその医薬用途
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN103703004B (zh) * 2011-12-31 2016-06-29 百济神州有限公司 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮
HK1204955A1 (zh) * 2012-02-07 2015-12-11 Eolas Therapeutics Inc. 取代的脯氨酸/哌啶用作食慾素受體拮抗劑
EA201491530A1 (ru) 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
CA2899030C (en) 2013-02-19 2021-03-09 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
HK1211923A1 (en) 2013-03-14 2016-06-03 赛拉根医药股份有限公司 Polycyclic estrogen receptor modulators and uses thereof
CA2911859A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
JP2016540767A (ja) 2013-12-06 2016-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 局所進行性又は転移性エストロゲン受容体陽性乳がんの治療のためのエストロゲン受容体調節因子
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
WO2015123355A1 (en) * 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9695166B2 (en) * 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
US9796686B2 (en) 2014-05-16 2017-10-24 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3H)-one derivatives
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
NZ731344A (en) 2014-10-09 2018-08-31 Guangdong Raynovent Biotech Co Ltd Hydroxyl purine compounds and applications thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016252753A1 (en) 2015-04-21 2017-11-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016279330B2 (en) * 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
CN107428758B (zh) * 2015-11-12 2020-08-04 浙江海正药业股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN113004273A (zh) * 2016-02-05 2021-06-22 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
CA3024615A1 (en) 2016-06-10 2017-12-14 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN109415361B (zh) * 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
JP7050770B2 (ja) * 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Also Published As

Publication number Publication date
EP3442971C0 (en) 2024-09-25
KR20220071293A (ko) 2022-05-31
TWI746535B (zh) 2021-11-21
CN112679495A (zh) 2021-04-20
BR112018070161A2 (pt) 2019-02-12
CA3017388C (en) 2024-03-12
US11065233B2 (en) 2021-07-20
AU2017242027A1 (en) 2018-10-11
US10959989B2 (en) 2021-03-30
IL285318B (en) 2022-09-01
CN113717170A (zh) 2021-11-30
US20200261428A1 (en) 2020-08-20
AU2022204025A1 (en) 2022-06-30
AU2020294196B2 (en) 2022-06-16
SG11201807708SA (en) 2018-10-30
CN112745316A (zh) 2021-05-04
CN109311870B (zh) 2021-09-21
AR108011A1 (es) 2018-07-04
JP6926189B2 (ja) 2021-08-25
WO2017172957A1 (en) 2017-10-05
IL261654B (en) 2021-08-31
IL285318A (en) 2021-09-30
CN109311870A (zh) 2019-02-05
EP3442971A1 (en) 2019-02-20
IL295050A (en) 2022-09-01
TW201736334A (zh) 2017-10-16
MX392461B (es) 2025-03-11
TW202235418A (zh) 2022-09-16
IL261654A (en) 2018-10-31
KR102401841B1 (ko) 2022-05-25
US20190142811A1 (en) 2019-05-16
JP2019515026A (ja) 2019-06-06
US20200261430A1 (en) 2020-08-20
KR20190002478A (ko) 2019-01-08
AU2017242027B2 (en) 2020-10-08
RU2018132037A (ru) 2020-05-12
US11065234B2 (en) 2021-07-20
EP3442971A4 (en) 2020-01-01
CA3017388A1 (en) 2017-10-05
ES2991862T3 (es) 2024-12-05
RU2018132037A3 (es) 2020-05-15
EP3442971B1 (en) 2024-09-25
MX2022005780A (es) 2022-06-09
RU2738646C2 (ru) 2020-12-15
AU2020294196A1 (en) 2021-01-28
JP2021176911A (ja) 2021-11-11
US20200261429A1 (en) 2020-08-20
CN112679495B (zh) 2023-03-28
US20210330651A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2022005780A (es) Moduladores de receptores estrogenicos.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
MX386859B (es) Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
EA201790921A1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
MX372914B (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX381597B (es) Inhibidores demetilasa-1 específica de lisina.
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
MX376632B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX395534B (es) Inhibidores de demetilasa-1 especifica de lisina.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX391865B (es) Inhibidores de demetilasa-1 especifica de lisina.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
CR20200214A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
PH12017501879A1 (en) Methods for treating cancer
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
UA117779C2 (uk) Піразини як модулятори gpr6
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
BR112015023383A2 (pt) compostocomposição farmacêutica; e método de modulação